The stock of Lifecore Biomedical Inc (LFCR) has gone down by -27.00% for the week, with a -27.36% drop in the past month and a -25.00% drop in the past quarter. The volatility ratio for the week is 22.24%, and the volatility levels for the past 30 days are 10.64% for LFCR. The simple moving average for the past 20 days is -18.47% for LFCR’s stock, with a -30.75% simple moving average for the past 200 days.
Is It Worth Investing in Lifecore Biomedical Inc (NASDAQ: LFCR) Right Now?
Lifecore Biomedical Inc (NASDAQ: LFCR) has a higher price-to-earnings ratio of 18.89x compared to its average ratio, The 36-month beta value for LFCR is at 0.97. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for LFCR is 28.31M, and currently, shorts hold a 9.95% of that float. The average trading volume for LFCR on September 03, 2024 was 265.39K shares.
LFCR) stock’s latest price update
Lifecore Biomedical Inc (NASDAQ: LFCR)’s stock price has gone rise by 14.81 in comparison to its previous close of 3.82, however, the company has experienced a -27.00% decrease in its stock price over the last five trading days. prnewswire.com reported 2024-09-02 that NEW YORK, Sept. 2, 2024 /PRNewswire/ — Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, both dates inclusive (the “Class Period”), of the important September 27, 2024 lead plaintiff deadline.
Analysts’ Opinion of LFCR
Stephens, on the other hand, stated in their research note that they expect to see LFCR reach a price target of $2, previously predicting the price at $11. The rating they have provided for LFCR stocks is “Equal-Weight” according to the report published on March 20th, 2023.
LFCR Trading at -17.98% from the 50-Day Moving Average
After a stumble in the market that brought LFCR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -51.79% of loss for the given period.
Volatility was left at 10.64%, however, over the last 30 days, the volatility rate increased by 22.24%, as shares sank -21.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.12% lower at present.
During the last 5 trading sessions, LFCR fell by -27.00%, which changed the moving average for the period of 200-days by -38.66% in comparison to the 20-day moving average, which settled at $5.31. In addition, Lifecore Biomedical Inc saw -29.24% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for LFCR
Current profitability levels for the company are sitting at:
- -0.06 for the present operating margin
- 0.33 for the gross margin
The net margin for Lifecore Biomedical Inc stands at 0.09. The total capital return value is set at -0.03. Equity return is now at value 20.97, with 3.46 for asset returns.
Based on Lifecore Biomedical Inc (LFCR), the company’s capital structure generated 0.7 points at debt to capital in total, while cash flow to debt ratio is standing at -0.0. The debt to equity ratio resting at 2.33. The interest coverage ratio of the stock is -0.4.
Currently, EBITDA for the company is 0.81 million with net debt to EBITDA at 40.38. When we switch over and look at the enterprise to sales, we see a ratio of 2.01. The receivables turnover for the company is 4.12for trailing twelve months and the total asset turnover is 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.08.
Conclusion
In conclusion, Lifecore Biomedical Inc (LFCR) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
